ChanTest Announces Phase II SBIR Grant to Optimize Cardiomyocyte-Based Assays
ChanTest, the leading CRO expert in ion channels and nonclinical cardiac safety testing, announces funding of a Phase II SBIR grant. ChanTest will use the grant from the National Heart Lung & Blood Institute to optimize drug safety and discovery assays using stem cell-derived human cardiomyocytes.
"This grant will allow us to optimize our industry-leading cardiomyocyte assays," said ChanTest's Principal Investigator Andrew Bruening-Wright, Ph.D. "With our collaborators at FDA, DSEC, and Leadscope, Inc., we have improved predictivity models based on currently available ChanTest services. Our nonclinical models will only get better as we fully integrate cardiomyocyte-based assays."
These cardiomyocyte assays are critical for improving the predictivity of nonclinical testing and reducing the use of animals as proposed in the NIH roadmap for drug discovery and the FDA's critical path initiative. The grant will also fund development of automated instrument-based services to increase throughput and drive down costs to meet the needs of ChanTest customers.
Dr. Arthur "Buzz" Brown, founder and CEO of ChanTest and co-PI on the grant, added "ChanTest has assembled an expert team to ensure success of this grant. We'll build on this success to improve drug discovery for other diseases in which ion channels play a critical role."
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
